# GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

> **NCT02095184** · NA · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 42 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02095184
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-25
- **Primary completion:** 2024-07-24
- **Final completion:** 2024-08-02
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** This study was terminated due to slow accrual, and this due to the changing practice patterns, and difficulties with insurance coverage for some of the study related tests, such as OncotypeDx.
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095184, "GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02095184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*